Novel Mechanistic Insights into the Anti-cancer Mode of Arsenic Trioxide

Author(s): Md Wahiduzzaman, Akinobu Ota*, Yoshitaka Hosokawa.

Journal Name: Current Cancer Drug Targets

Volume 20 , Issue 2 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Arsenic, a naturally-occurring toxic element, and a traditionally-used drug, has received a great deal of attention worldwide due to its curative anti-cancer properties in patients with acute promyelocytic leukemia. Among the arsenicals, arsenic trioxide has been most widely used as an anti-cancer drug. Recent advances in cancer therapeutics have led to a paradigm shift away from traditional cytotoxic drugs towards the targeting of proteins closely associated with driving the cancer phenotype. Due to the diverse anti-cancer effects of ATO on different types of malignancies, numerous studies have made efforts to uncover the mechanisms of ATO-induced tumor suppression. From in vitro cellular models to studies in clinical settings, ATO has been extensively studied. The outcomes of these studies have opened doors to establishing improved molecular-targeted therapies for cancer treatment. The efficacy of ATO has been augmented by combination with other drugs. In this review, we discuss recent arsenic-based cancer therapies and summarize the novel underlying molecular mechanisms of the anti-cancer effects of ATO.

Keywords: Arsenic, anti-cancer drug, chemotherapy, apoptosis, reactive oxygen species, acute promyelocytic leukemia.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 2
Year: 2020
Page: [115 - 129]
Pages: 15
DOI: 10.2174/1568009619666191021122006
Price: $65

Article Metrics

PDF: 6

Special-new-year-discount